Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

GAITHERSBURG, Md. , Nov. 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the Jefferies London Healthcare Conference.

Novavax to Participate in Jefferies London Healthcare Conference

Novavax reported a net loss of $0.76/share and $84.5M in revenue, beating estimates but cutting guidance due to lower COVID-19 vaccine sales. Revenue has declined since 2022, prompting a substantial cost reduction program set to refocus the company on 4 key value drivers. A collaboration with Sanofi offers flexibility and potential growth, allowing Novavax to focus on developing a COVID-19/influenza combination (CIC) and seasonal influenza vaccines.

Novavax Q3 Earnings Disappoint, But A Turnaround May Be Underway

Novavax, Inc. (NASDAQ:NVAX ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Luis Sanay - Vice President, Investor Relations John Jacobs - President and Chief Executive Officer John Trizzino - President and Chief Operating Officer Robert Walker - Senior Vice President and Chief Medical Officer Jim Kelly - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Eric Joseph - JPMorgan Vernon Bernardino - H.C.

Novavax, Inc. (NVAX) Q3 2024 Earnings Call Transcript

Novavax (NVAX) shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.

Novavax Stock is Slipping After the Vaccine Maker Cut its Outlook Again

Novavax Inc.'s stock fell 4% Tuesday after the company cut its full-year guidance, offsetting a narrower-than-expected third-quarter loss and better-than-expected revenue.

Novavax's stock slides 7% as guidance cut offsets narrower-than-expected third-quarter loss

Novavax (NVAX) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to loss of $1.26 per share a year ago.

Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates

The vaccine maker posted a narrower third-quarter loss than expected at 76 cents a share. Revenue was $85 million, compared with the $74 million analysts expected.

Novavax Stock Dives Even Though Results Beat Forecasts

NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violations of federal securities laws. On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company's combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine.

Lost Money on Novavax, Inc. (NVAX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to Sanofi.

Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales

U.S. FDA removes clinical hold on Investigational New Drug application for COVID-19-Influenza Combination and stand-alone influenza vaccine candidates Achieved total revenue of $85 million in the third quarter of 2024 Ended the third quarter of 2024 with $1 billion in cash and receivables Received authorization from U.S. FDA and European Commission for updated 2024-2025 formula COVID-19 vaccine in individuals aged 12 and older Outlined R&D strategy based on its proven technology platform Updates full year 2024 financial guidance Company to host conference call today at 8:30 a.m. ET GAITHERSBURG, Md.

Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights

Novavax (NVAX) shares edged higher Monday after the drugmaker announced that federal regulators have given the company the go-ahead to continue testing its combination COVID-19-flu and standalone flu vaccines.

Novavax Gets FDA Approval To Resume Testing Two Vaccines After Clinical Hold

Axsome Therapeutics

AstraZeneca

Prothena

Theravance Biopharma

Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week.

Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?

On NVAX's third-quarter earnings call, investors will likely seek updates on management???s ongoing discussions with the FDA to remove the clinical hold on its two vaccine programs.

Novavax to Report Q3 Earnings: Here's What to Expect

NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violations of federal securities laws. On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company's combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine.

Levi & Korsinsky Announces an Investigation on Behalf of Novavax, Inc. (NVAX) Shareholders Who May Have Been Affected by Fraud

The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.

US FDA lifts clinical hold on Novavax's combo COVID-flu shot

GAITHERSBURG, Md. , Nov. 11, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on Novavax's Investigational New Drug (IND) application for its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates.

U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

Shareholders that lost money on Novavax, Inc.(NVAX) should contact Levi & Korsinsky about Securities Fraud Investigation - NVAX

NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violations of federal securities laws. On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company's combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine.

NVAX ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Novavax, Inc. Shareholders Who Lost Money

An Investigation Has Commenced on Behalf of Novavax, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your NVAX Losses

NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violations of federal securities laws. On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company's combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine.

Levi & Korsinsky Reminds Shareholders of an Investigation into Novavax, Inc. (NVAX) Regarding Potential Securities Fraud Allegations

Did Novavax, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- NVAX

Novavax said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency related to its COVID-19 vaccine supply agreement.

Novavax, UK terminate vaccine supply agreement

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

GAITHERSBURG, Md. , Nov. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its third quarter 2024 financial results and operational highlights at 8:30 a.m.

Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024

NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violations of federal securities laws. On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company's combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine.

News for Novavax Stock (NVAX)